Isla P Garraway

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2935796/publications.pdf

Version: 2024-02-01

567281 642732 26 941 15 23 citations h-index g-index papers 31 31 31 1872 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics, 2020, 52, 790-799.	21.4	174
2	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.9	147
3	Human prostate sphereâ€forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate, 2010, 70, 491-501.	2.3	130
4	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature Medicine, 2018, 24, 1887-1898.	30.7	113
5	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research, 2019, 79, 3636-3650.	0.9	47
6	Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Network Open, 2022, 5, e2144027.	5.9	43
7	Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. PLoS ONE, 2016, 11, e0163232.	2.5	35
8	Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells. Oncotarget, 2016, 7, 84645-84657.	1.8	33
9	Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. Cancer, 2021, 127, 403-411.	4.1	29
10	Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget, 2017, 8, 46710-46727.	1.8	25
11	Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis. Convergent Science Physical Oncology, 2018, 4, 015003.	2.6	23
12	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics, 2019, 9, 2812-2826.	10.0	20
13	Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate, 2016, 76, 125-139.	2.3	17
14	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer, 2019, 19, 291.	2.6	17
15	Impact of treatment on progression to castrationâ€resistance, metastases, and death in men with localized highâ€grade prostate cancer. Cancer Medicine, 2017, 6, 163-172.	2.8	16
16	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	5.9	16
17	The Role of Opioids and Their Receptors in Urological Malignancy: A Review. Journal of Urology, 2020, 204, 1150-1159.	0.4	14
18	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer, 2020, 20, 398.	2.6	13

#	Article	IF	CITATIONS
19	Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men. Journal of the National Cancer Institute, 2021, 113, 1343-1351.	6.3	11
20	Targeting the RANKL Pathway: Putting the Brakes on Prostate Cancer Progression in Bone. Journal of Clinical Oncology, 2013, 31, 3838-3840.	1.6	7
21	The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1364-1369.	1.2	5
22	Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer. Journal of the National Cancer Institute, 2022, 114, 592-599.	6.3	5
23	Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A meta-analysis of eight randomized trials Journal of Clinical Oncology, 2020, 38, 327-327.	1.6	1
24	Evaluating PSA nadir drift in high-risk and metastatic prostate cancer Journal of Clinical Oncology, 2016, 34, 310-310.	1.6	0
25	The Personalized Medicine for Prostate Cancer (PMPC) Study: The role of race, genomics, and patient complexity in treatment outcomes Journal of Clinical Oncology, 2020, 38, 302-302.	1.6	0
26	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 715-727.	2. 5	0